189 related articles for article (PubMed ID: 36110930)
21. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
23. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
24. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.
Hsu NC; Nien PY; Yokoyama KK; Chu PY; Hou MF
Biochem Biophys Res Commun; 2013 Nov; 441(2):514-8. PubMed ID: 24177010
[TBL] [Abstract][Full Text] [Related]
25. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
[TBL] [Abstract][Full Text] [Related]
26. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
[TBL] [Abstract][Full Text] [Related]
27. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
28. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
29. Functional roles of CSPG4/NG2 in chondrosarcoma.
Jamil NS; Azfer A; Worrell H; Salter DM
Int J Exp Pathol; 2016 Apr; 97(2):178-86. PubMed ID: 27292772
[TBL] [Abstract][Full Text] [Related]
30. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
31. CSPG4 in cancer: multiple roles.
Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
[TBL] [Abstract][Full Text] [Related]
32. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
33. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
[TBL] [Abstract][Full Text] [Related]
34. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
35. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
36. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
[TBL] [Abstract][Full Text] [Related]
37. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
[TBL] [Abstract][Full Text] [Related]
38. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
39. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma.
Wang Y; Sabbatino F; Wang X; Ferrone S
Methods Mol Biol; 2014; 1102():523-35. PubMed ID: 24258997
[TBL] [Abstract][Full Text] [Related]
40. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.
Fenton M; Whiteside TL; Ferrone S; Boyiadzis M
Oncol Res; 2015; 22(2):117-21. PubMed ID: 25706398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]